Literature DB >> 11285552

Randomized trials of radiation therapy in adult low-grade gliomas.

K H Henderson1, E G Shaw.   

Abstract

There are two central questions in the radiotherapeutic management of the adult patient with a supratentorial low-grade (WHO grade II) astrocytoma, oligo-astrocytoma, or oligodendroglioma. The first question is one of timing. Following tissue diagnosis with or without maximum surgical resection, should immediate postoperative radiation therapy (RT) be given, or should RT be deferred to the time of local recurrence? The second question is one of dose. Assuming RT is given, should lower doses (ie, approximately 45-50 Gray (Gy)) or higher doses (ie, approximately 60-65 Gy) be administered? One Phase III prospective randomized clinical trial addressing the first question and two addressing the second question have been performed. Their results suggest that delayed (versus immediate) RT and low-dose (versus high-dose) RT are both acceptable treatment strategies despite the bias amongst radiation oncologists (primarily based on retrospective data) that immediate and high-dose RT would result in better outcome. The schema of the ongoing Radiation Therapy Oncology Group study is presented. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11285552     DOI: 10.1053/srao.2001.21424

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  10 in total

Review 1.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

2.  Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.

Authors:  Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

3.  Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy.

Authors:  Matthias Philipp Lichy; Christian Plathow; Daniela Schulz-Ertner; Hans-Ulrich Kauczor; Heinz-Peter Schlemmer
Journal:  Neuroradiology       Date:  2005-09-02       Impact factor: 2.804

4.  Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.

Authors:  Gokhan Ozyigit; Cem Onal; Murat Gurkaynak; Figen Soylemezoglu; Faruk Zorlu
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

5.  Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.

Authors:  S E Combs; R Ahmadi; D Schulz-Ertner; C Thilmann; J Debus
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 8.  Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults.

Authors:  Lynn S Ashby; William R Shapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

9.  Long-term follow-up in adult patients with low-grade glioma (WHO II) postoperatively irradiated. Analysis of prognostic factors.

Authors:  Anna Mucha-Małecka; Bogdan Gliński; Marcin Hetnał; Magdalena Jarosz; Jacek Urbański; Beata Frączek-Błachut; Paweł Dymek; Krzysztof Małecki; Agnieszka Chrostowska
Journal:  Rep Pract Oncol Radiother       Date:  2012-02-10

10.  Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.

Authors:  J Vesper; E Graf; C Wille; J Tilgner; M Trippel; G Nikkhah; Cb Ostertag
Journal:  BMC Neurol       Date:  2009-07-16       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.